Febuxostat dose requirement according to renal function in patients who achieve target serum urate levels: A retrospective cohort study
Authors' conclusion
Among patients who achieved SU target, those with severely decreased renal function (CKD 4-5) required a lower febuxostat dose to achieve the target SU level compared to patients with normal or mild renal impairment.
Study context
- Population
- Gout patients treated with febuxostat with initial serum urate (SU) level >6 mg/dL; median age 52.0 years (IQR, 41.0–63.0), 711 (91.4%) menof 873 included
- Participants
- 778 patients
- Exposure
- Febuxostat dose at SU target achievement by renal function: Chronic kidney disease (CKD) 4-5 vs CKD 3 vs normal
- Outcome
- Febuxostat dose (average daily dosage) at the time of SU target (<6 mg/dL) achievement
Main finding
As reported in the abstract
Febuxostat dose at SU target achievement, in those who achieved target SU
CKD 4-5 vs CKD 3: P < 0.01 · CKD 4-5 vs Normal: P < 0.01
- CKD stage 4-5 negatively correlated with febuxostat dose requirement (Beta)
- −2.334
Observational data: associations, not effects.
Further findings
Mean SU at febuxostat initiation
- Mean SU at febuxostat initiation: P<0.001
Time to target SU
- Median time to target SU (months)
- 4.0 (1.9-9.6)
Original publication
Febuxostat dose requirement according to renal function in patients who achieve target serum urate levels: A retrospective cohort study. Joint Bone Spine. Published 29 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →